Signal Genetics, a predictive genetic testing company focused on oncology, recently announced that it would work with pharmaceutical company Array BioPharma to advance both companies’ goals of finding biomarkers for myeloma patients.
CytRx Puts Its Cancer Pipeline to the Test
All told, the Los Angeles-based company could have six to eight trials running simultaneously in the coming months.
[OneMedForum] Senesco Technologies: Life and Death on a Cellular Level
“Programmed cell death” sounds a bit sinister, but it’s actually a normal and healthy process.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.
Keryx Biopharma: Well-Funded Comeback Story with Multiple Catalysts
Keryx Biopharmaceuticals, Inc. is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA.
Onyx Pharmaceuticals to Acquire Proteolix
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.
